Reinnervate Ltd has announced that it has launched and commenced shipments of Alvetex®Scaffold 96 well plates to customers.
“We are very pleased that the pent up demand for Alvetex®Scaffold in a 96 well plate format has meant we have immediately received orders from several Pharmaceutical customers and an Oncology-focused CRO”, commented Richard Rowling, Commercial Director of Reinnervate.
Rowling continued, “The work we have done with customers over the last 12 months has clearly demonstrated the need for a simple and reproducible 3D cell culture platform and now with a 96 well plate format, we can push deeper into the drug discovery and screening markets.”
Prof. Stefan Przyborski, founder and CSO of Reinnervate described a typical application in cancer cell cyto-toxicity testing; “The Alvetex®Scaffold 96 well plates allow scientists to grow tumour cells in a way that better mimics the way these cells grow in vivo. It is then very simple to test the cytotoxic effect of novel or existing anti-cancer compounds using standard cell health assays such as MTT, XTT, Cell Titer-Glo® and many others. We can then easily retrieve RNA and protein from the drug treated cells to study mechanism of action and look for biomarkers”.
He went on to say, “We have also shown that the Alvetex®Scaffold 96 well plates work seamlessly with automated platforms such as the Tecan Evo 200.”